The short answer
Lotiglipron reduced weight, but liver-enzyme findings led its developer to stop the trial and development program.
What was studied?
This phase 2 study randomized 902 adults across separate type 2 diabetes and obesity groups; 901 received treatment. The obesity group included 389 people without diabetes.
Researchers compared different daily lotiglipron tablet regimens with placebo. Treatment was planned for at least 32 weeks.
Percent of starting weight; on-treatment; active group assigned 200 mg target
Original visual based on the study.
| Group or measure | Result |
|---|---|
| Lotiglipron 160 mg at week 20 | 7.47% |
| Placebo | 1.84% |
What happened?
No participant completed the planned treatment phase before the study stopped.
At 20 weeks, one obesity regimen produced an estimated 7.47% weight loss versus 1.84% with placebo. That group was assigned a 200 mg target but had reached only 160 mg by that visit.
Liver enzymes rose above three times the laboratory upper limit in 6.0% receiving lotiglipron versus 1.6% receiving placebo in the obesity group. Digestive side effects also frequently interrupted treatment.
How should we read this?
Early stopping changed the analysis and prevented evaluation of the planned 32-week outcomes. These results cannot establish longer-term benefit or safety.
Liver-enzyme elevations are not the same as proven liver failure. The findings concern lotiglipron, not all oral GLP medicines.
Pfizer funded the study.